id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-P-1808-0004,FDA,FDA-2025-P-1808,"Determination That Klonopin (Clonazepam) Tablets, 0.125 Milligrams and 0.25 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness",Notice,Determinations,2026-02-23T05:00:00Z,2026,2,,,2026-02-23T19:17:58Z,2026-03495,0,0,09000064b91d0373
FDA-2025-P-1808-0005,FDA,FDA-2025-P-1808,Final Response,Other,Response(s),2026-02-23T05:00:00Z,2026,2,2026-02-23T05:00:00Z,,2026-02-24T00:06:30Z,,0,0,09000064b91d0e0d
FDA-2025-P-1808-0003,FDA,FDA-2025-P-1808,"Interim Response Letter from FDA CDER to Hyman, Phelps & McNamara, P.C.",Other,Response(s),2025-12-15T05:00:00Z,2025,12,2025-12-15T05:00:00Z,,2025-12-16T01:43:54Z,,0,0,09000064b90d4198
FDA-2025-P-1808-0001,FDA,FDA-2025-P-1808,"Citizen Petition from Hyman, Phelps & McNamara, P.C.",Other,Citizen Petition,2025-06-23T04:00:00Z,2025,6,2025-06-23T04:00:00Z,,2026-02-23T19:45:31Z,,0,0,09000064b8e1f2bc
FDA-2025-P-1808-0002,FDA,FDA-2025-P-1808,"Acknowledgment Letter from FDA DMB to Hyman, Phelps & McNamara, P.C.",Other,Acknowledgement Letter/Receipt,2025-06-23T04:00:00Z,2025,6,2025-06-23T04:00:00Z,,2025-06-23T18:55:37Z,,0,0,09000064b8e1f2be